ERBB2 and neoplasm: BC recurrence also differed substantially across surrogate subtypes (Table 2) with a 10-years cumulative incidence of 32.5 % among TN (27 % after 5 years) and about 20 % among women with HR + or HER2+ tumours (11.3 % and 14.5 % after 5 years, respectively).